A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC).

Trial Profile

A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC).

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2012

At a glance

  • Drugs Firtecan pegol (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Oct 2012 Planned End Date changed from 1 Sep 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov record.
    • 04 Jun 2012 Final results were reported at the Annual Meeting of the American Society of Clinical Oncology, and in an Enzon Pharmaceuticals media release.
    • 04 Jun 2012 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top